文献类型： 外文期刊

作者： Xie, Di ⁴ ; Chen, Fan ¹ ; Zhang, Yuanyuan ² ; Shi, Bei ⁶ ; Song, Jiahui ⁷ ; Chaudhari, Kiran ⁸ ; Yang, Shao-Hua ⁸ ; Zhang, Gary J. ⁴ ; Sun, Xiaoli ³ ; Taylor, Hugh S. ⁴ ; Li, Da ⁷ ; Huang, Yingqun ⁴ ;

作者机构： 1.Hubei Acad Agr Sci, Hubei Key Lab Anim Embryo Engn & Mol Breeding, Wuhan 430070, Hubei, Peoples R China

2.Nanjing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Nanjing 210029, Jiangsu, Peoples R China

3.Nantong Univ, Ctr Reprod Med, Dept Obstet & Gynecol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China

4.Yale Univ, Dept Obstet Gynecol & Reprod Sci, Sch Med, New Haven, CT 06510 USA

5.Yale Univ, Yale Ctr Mol & Syst Metab, Sch Med, New Haven, CT 06520 USA

6.China Med Univ, Med Basic Expt Teaching Ctr, Shenyang 110004, Peoples R China

7.China Med Univ, Ctr Reprod Med, Shengjing Hosp, Shenyang 110004, Peoples R China

8.Univ North Texas, Inst Hlth Aging, Dept Pharmacol & Neurosci, Hlth Sci Ctr, Ft Worth, TX 76107 USA

关键词： metformin; Let-7; TET3; liver; diabetes

期刊名称：PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA （ 影响因子：12.779； 五年影响因子：13.45 ）

ISSN： 0027-8424

年卷期： 2022 年 119 卷 14 期

页码：

收录情况： SCI

摘要： Metformin, the frontline antidiabetic drug, has gained increasing attention for the prevention and treatment of aging, cancer, and cardiovascular disease. Yet a clear mechanistic understanding of its action is still lacking, largely due to the suprapharmacological concentrations of metformin used in most studies. Here, we report an inhibition of glucose production by primary hepatocytes from dietary and genetic mouse models of type 2 diabetes (T2D) using metformin at clinically relevant concentrations. Mechanistically, metformin up-regulates microRNA let-7 that in turn down-regulates TET3, evoking a change in the ratio of hepatocyte nuclear factor 4 alpha (HNF4 alpha) isoforms and subsequent inhibition of key gluconeogenic genes. Importantly, this let-7-mediated mechanism is faithfully recapitulated in mice with T2D chronically treated with therapeutic doses of metformin. Furthermore, hepatic delivery of let-7 ameliorates hyperglycemia and improves glucose homeostasis in diabetic mice, whereas liver-specific inhibition of let-7 abrogates these beneficial effects of metformin. Moreover, let-7 overexpression decreases glucose production from primary hepatocytes from obese humans. Thus, we propose the reactivation of a let-7-dependent pathway that is pathologically repressed in the liver of diabetes as a major mechanism of metformin action and that liver-specific delivery of let-7 represents a potential therapeutic for T2D. Our findings are also pertinent to the development of therapeutic strategies for other chronic diseases.